HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Factors associated with emergence of pristinamycin-resistant Staphylococcus aureus in a dermatology department: a case-control study.

AbstractBACKGROUND:
Pristinamycin is used for the treatment of Staphylococcus aureus skin infection. Staphylococcus aureus pristinamycin resistance is usually low. The frequency of pristinamycin-resistant S. aureus (PRSA) increased in the Caen University Hospital dermatology department from 1% in 1998 to >11% in 1999-2002.
OBJECTIVES:
This study aimed to identify the factors associated with PRSA acquisition.
METHODS:
Incidences of PRSA and pristinamycin consumption were calculated for the dermatology department and for the rest of the hospital from 1997 to 2007. Individual factors of PRSA acquisition in the dermatology department from 2000 to 2001 were analysed in a retrospective case-control study including 23 cases of PRSA skin colonization or infection and 46 controls with pristinamycin-susceptible S. aureus. Clonal relatedness of isolates was analysed by pulsed-field gel electrophoresis and pristinamycin resistance genes were detected by polymerase chain reaction. Conditional logistic regression was performed to analyse the relationship between pristinamycin resistance and epidemiological and microbiological data.
RESULTS:
PRSA frequency and pristinamycin consumption were significantly higher in the dermatology department than in other hospital departments. Two epidemic clones of two and six isolates were found for periods of 1 and 2 months, respectively. Thirteen of the 23 PRSA isolates (57%), including all isolates of the two epidemic clones, were found 48 h after the hospitalization or later. PRSA was associated with pristinamycin use during the previous year [odds ratio (OR) 5.60, 95% confidence interval (CI) 1.41-22.22], cumulative use of antibiotics exceeding 1 week during the previous year (OR 4.63, 95% CI 1.47-14.54) and methicillin resistance (OR 6.35, 95% CI 1.38-29.15).
CONCLUSIONS:
Results suggest that antimicrobial selective pressure and microbial cross-transmission are involved in PRSA acquisition.
AuthorsL Verneuil, C Marchand, J S Vidal, R Ze Bekolo, C Daurel, G Lebouvier, D Leroy, R Leclercq
JournalThe British journal of dermatology (Br J Dermatol) Vol. 163 Issue 2 Pg. 329-33 (Aug 2010) ISSN: 1365-2133 [Electronic] England
PMID20426786 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Bacterial Agents
  • Pristinamycin
Topics
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents (therapeutic use)
  • Case-Control Studies
  • Cross Infection (drug therapy, epidemiology, microbiology)
  • Drug Resistance, Bacterial
  • Electrophoresis, Gel, Pulsed-Field
  • Female
  • Genotype
  • Humans
  • Logistic Models
  • Male
  • Microbial Sensitivity Tests
  • Polymerase Chain Reaction
  • Pristinamycin (therapeutic use)
  • Retrospective Studies
  • Staphylococcal Infections (drug therapy, epidemiology)
  • Staphylococcal Skin Infections (drug therapy, epidemiology)
  • Staphylococcus aureus (drug effects, genetics, isolation & purification)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: